{"filings":[{"id":98661,"accession_number":"0001493152-26-021112","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Ernexa Therapeutics effects 1-for-25 reverse stock split, effective May 4, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1-for-25 ratio; trading on split-adjusted basis began at market open on May 4, 2026.","Certificate of Amendment filed with Delaware Secretary of State on May 1, 2026.","New CUSIP number for common stock post-split: 114082407.","Common stock (ERNA) and warrants (ERNAW) trade on Nasdaq under split-adjusted terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114268,"accession_number":"0001493152-26-011922","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2026-03-20T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Ernexa Therapeutics receives Nasdaq delisting bid-price notice; ineligible for cure due to prior reverse split","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on March 18, 2026 for failure to maintain $1.00 minimum bid price for 30 consecutive business days.","Company not eligible for standard 180-day compliance period under Rule 5810(c)(3)(A)(iv) due to reverse stock split within past year.","Intends to request hearing before Nasdaq Hearing Panel; request stays suspension/delisting pending panel decision and possible 180-day extension.","No assurance that panel will grant extension or that securities (ERNA, ERNAW) will remain listed on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114267,"accession_number":"0001493152-26-008182","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Ernexa Therapeutics posts updated investor presentation on February 26, 2026","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Updated presentation replaces the December 11, 2025 version; available on company website.","Presentation furnished under Item 7.01 Regulation FD; no financial statements or material agreements attached.","Specific content of the update is not disclosed in the filing; investors should review the presentation directly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114266,"accession_number":"0001493152-26-006227","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2026-02-11T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Ernexa Therapeutics prices $10.5M public offering of 21M shares and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 21M shares of common stock (or equivalents) and warrants to buy 21M shares at $0.50 per unit.","Gross proceeds expected ~$10.5M; net proceeds for development programs, working capital, and general purposes.","Warrants exercisable at $0.68/share, expire 5 years from issuance or 180 days after release of Phase 1 ERNA-101 data.","Brookline Capital Markets acted as exclusive placement agent; offering closed Feb 10, 2026.","Potential additional $14.3M if all warrants exercised on cash basis (no assurance given)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130643,"accession_number":"0001493152-25-027167","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Ernexa Therapeutics posts new investor presentation; details not disclosed in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company made a December 2025 investor presentation available via 8-K and its website.","No financial or operational data from the presentation is included in the filing.","Investors will need to access the company website to view the presentation content."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147189,"accession_number":"0001641172-25-018009","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2025-07-07T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Ernexa Therapeutics dismisses Grant Thornton, appoints Haskell & White as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dismissal of Grant Thornton effective June 30, 2025; appointment of Haskell & White effective July 1, 2025, approved by Audit Committee.","Grant Thornton's reports for FY 2023 and 2024 included a going-concern explanatory paragraph but were otherwise unqualified.","No disagreements with Grant Thornton; only disclosed material weakness in FY 2023 internal controls from lack of technical accounting proficiency.","Grant Thornton provided a letter to the SEC regarding the dismissal, attached as Exhibit 16.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165799,"accession_number":"0001641172-25-014877","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Ernexa Therapeutics effects 1-for-15 reverse stock split effective June 12, 2025","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Certificate of amendment filed with Delaware Secretary of State on June 10, 2025.","Reverse stock split ratio is 1-for-15.","Effective date of reverse stock split is June 12, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165798,"accession_number":"0001641172-25-014318","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["3.02","8.01"],"status":"ready","headline":"Ernexa completes second closing of $6M private placement; total $7M raised; expects to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Second closing on June 9, 2025: issued 47.7M shares and 9.3M pre-funded warrants for ~$6.0M gross proceeds.","Combined with April 2 closing, total 57.7M shares and 9.8M warrants issued for ~$7.0M.","Proceeds to be used for working capital and repaying certain notes.","Company believes it now satisfies Nasdaq Stockholders' Equity Standard ($2.5M minimum) as alternative to Market Value Standard.","Pre-funded warrants exercisable at $0.005 per share with 4.99%/9.99% beneficial ownership limitation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165797,"accession_number":"0001641172-25-013249","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Ernexa shareholders approve reverse stock split, share increase to 150M, and written consent","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected all five director nominees: James Bristol, Peter Cicala, Sanjeev Luther, Elena Ratner, William Wexler.","Approved amendment to increase authorized common stock from 100M to 150M shares.","Approved reverse stock split at Board's discretion within 1-for-10 to 1-for-15 ratio.","Approved stockholder action by written consent, removing meeting-only requirement.","Ratified Grant Thornton as auditor for 2025 and approved potential issuance >20% under March 31 securities purchase agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165800,"accession_number":"0001641172-25-002514","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2025-04-03T23:59:59+00:00","items":["1.01","3.02","5.08","9.01"],"status":"ready","headline":"Eterna Therapeutics raises up to $7.3M in private placement; resets annual meeting to June 2","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initial closing on April 2: sold 9.93M shares and 509,736 pre-funded warrants for $1.1M.","Second closing of $6.2M (48.33M shares, 10.54M warrants) subject to stockholder approval by June 30 (or July 30 if SEC reviews).","Purchase price $0.1046 per share; pre-funded warrants at $0.0996 with $0.005 exercise price.","Investors include existing 32% holder Charles Cherington and former director Nicholas Singer.","2025 annual meeting moved to June 2; stockholder proposal deadline is April 13."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183362,"accession_number":"0001641172-25-000681","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2025-03-26T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Eterna Therapeutics renames to Ernexa Therapeutics Inc. effective March 26, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company changed its name from Eterna Therapeutics Inc. to Ernexa Therapeutics Inc.","Filed Certificate of Amendment to Restated Certificate of Incorporation with Delaware Secretary of State.","Adopted amended and restated bylaws solely to reflect the name change.","Effective date of name change: March 26, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183361,"accession_number":"0001641172-25-000300","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2025-03-24T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Eterna Therapeutics issues $750K promissory note to insider Charles Cherington at 5% due June 2025","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $750,000 promissory note to Charles Cherington, who owns ~32% of ERNA shares.","Note bears 5% annual interest, payable at maturity; default rate 7%.","Matures on earliest of June 15, 2025, or when Eterna raises >$5M in equity/convertible debt.","Cherington also holds a $1.5M note from March 11, 2025, making total insider debt $2.25M.","Note includes customary events of default, cross-default >$50k, and bankruptcy clauses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183360,"accession_number":"0001493152-25-010049","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2025-03-12T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Eterna Therapeutics issues $1.5M promissory note to Charles Cherington at 5%","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Principal amount $1,500,000 at 5.0% annual interest, paid at maturity.","Matures June 15, 2025, or earlier if Eterna raises >$5M in equity or convertible debt.","Default rate set at 7.0% per annum on overdue amounts.","Proceeds received on March 11, 2025; loan can be prepaid without penalty.","Cross-default triggered if Eterna fails to pay >$50K in other debt after grace period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183359,"accession_number":"0001493152-25-006446","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["5.08"],"status":"ready","headline":"Eterna Therapeutics sets 2025 annual meeting for May 1; shareholder proposals due Feb 23","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting date: May 1, 2025; over 30 days before one-year anniversary of 2024 meeting.","Stockholder proposals and director nominations must be received by Feb 23, 2025.","Rule 14a-8 proposals also due Feb 23, 2025; submissions to Cambridge, MA office."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183358,"accession_number":"0001493152-25-001704","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["3.01","5.02"],"status":"ready","headline":"Eterna receives Nasdaq delisting notice for low MVLS; board changes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq notified Eterna on Jan 6, 2025 that MVLS was below $35M for 35 consecutive business days.","Company has 180-day cure period (until July 7, 2025) to regain compliance with MVLS standard.","Director Dorothy Clarke resigned Jan 6, 2025; no disagreement with Company; remains general counsel.","Dr. Elena Ratner appointed to Board effective Jan 7, 2025; determined independent director."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183357,"accession_number":"0001493152-25-000246","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2025-01-03T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Eterna Therapeutics receives Nasdaq bid price deficiency notice; 180-day cure period until June 30, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Notice received December 30, 2024: closing bid price below $1 for 30 consecutive business days.","Company has until June 30, 2025 to regain compliance for 10 consecutive business days.","If not cured, may request a second 180-day period if other listing standards are met.","Stock continues to trade on Nasdaq under symbol ERNA with no immediate delisting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199950,"accession_number":"0001493152-24-042902","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2024-10-29T23:59:59+00:00","items":["1.01","8.01","3.02","5.07","9.01"],"status":"ready","headline":"Eterna Therapeutics closes $1.1M private placement, exchanges debt for equity, addresses Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved issuance of shares for September 2024 transactions at Oct 29 annual meeting.","Closed private placement: issued 1,401,994 shares + 115,000 pre-funded warrants; gross proceeds $1.1M.","Exchange transactions: issued 38,302,029 shares for outstanding warrants and convertible notes.","Bridge notes converted: 6,244,237 shares + 1,764,000 pre-funded warrants; $0.50 conversion price.","Post-closing cap: ~51.4M shares outstanding; Nasdaq hearing on Nov 12 to address equity compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215959,"accession_number":"0001493152-24-038532","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2024-09-27T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Eterna Therapeutics enters exclusive license with Factor Bioscience for cancer, autoimmune, rare disease tech","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive license in cancer, autoimmune disorders, and rare diseases; replaces Nov 2023 and prior Exacis licenses.","Pays Factor $208,333/month for first 12 months and $50,000/month for first 9 months for patent costs.","Initial term one year, auto-renews; Eterna may terminate for any reason with 90 days notice.","Factor to provide services and materials to facilitate development and scale-up at third-party facilities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215958,"accession_number":"0001493152-24-038129","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2024-09-25T23:59:59+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"Eterna raises $3.9M via 12% notes; proposes debt/warrant exchange for 38.3M shares","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Closed $3.9M 12.0% senior convertible note private placement; net proceeds for general corporate purposes.","Agreed to sell 1,516,997 shares at $0.75/share for $1.1M in a separate common stock private placement.","Proposes to exchange outstanding convertible notes and warrants for ~38.3M shares, subject to stockholder approval.","Annual meeting postponed from Sept 27 to Oct 29, 2024; stockholder proposals due Oct 5.","Support agreements covering ~48% of outstanding shares commit to vote in favor of stockholder approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215957,"accession_number":"0001493152-24-037815","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2024-09-23T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Eterna Therapeutics receives Nasdaq delisting notice for failure to regain compliance with equity rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On Sept 17, 2024, Nasdaq determined Eterna did not meet the extension terms to demonstrate compliance with the Minimum Stockholders' Equity Rule (stockholders' equity < $2.5M as of Dec 31, 2023).","Trading of ERNA common stock will be suspended on Sept 26, 2024 unless a hearing request is filed by Sept 24, 2024.","Company intends to timely request a hearing with Nasdaq's Hearings Panel to appeal the determination; a stay will be in effect pending decision.","Hearings typically scheduled 30-45 days after request; panel decision within 30 days of hearing; no assurance of success.","If appeal fails or no request, a Form 25-NSE will be filed, removing ERNA from Nasdaq listing and registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215956,"accession_number":"0001493152-24-033119","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2024-08-19T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Eterna Therapeutics sets 2024 annual meeting for Sept 27; proposal deadline Aug 29","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual meeting scheduled for September 27, 2024.","Stockholder proposals and nominations must be received by August 29, 2024.","Date is >30 days from 2023 annual meeting anniversary, triggering special notice timeline.","All notices must be directed to company's principal executive offices per bylaws."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}